Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES2B-C001 + ISA 51 VD
- Development stage
- Unknown
- Lead developer
- ExpreS2ion Biotechnologies
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ES2B-C001 + ISA 51 VD is a combination therapeutic candidate comprising **ES2B-C001**, a virus-like particle (VLP)-based vaccine targeting the extracellular domain of **HER2** (human epidermal growth factor receptor 2), and **ISA 51 VD** (Montanide ISA 51), a water-in-oil emulsion adjuvant designed to enhance immunogenicity. The combination aims to induce a potent polyclonal anti-HER2 immune response for the treatment of **HER2-expressing cancers**, primarily metastatic breast cancer. ES2B-C001 acts as a HER2 antagonist, generating anti-HER2 antibodies and eliciting cellular immune responses. ISA 51 VD enhances the cytotoxic T-lymphocyte response and prolongs antigen presentation, thereby boosting vaccine efficacy. Preclinical studies have shown that the combination effectively inhibits tumor growth, prevents metastasis, and sustains long-term immune protection in HER2-positive tumor models. Clinical trials for this combination are in phase I for HER2-positive metastatic breast cancer[1][3][5][7].
- Other names
- Montanide ISA 51 (for ISA 51 VD)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ES2B-C001 + ISA 51 VD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ES2B-C001 + ISA 51 VD.